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Abstract
Background: Occult hepatitis B infections are becoming a major global threat, but the available data on its prevalence in various 
parts of  the world are often divergent.
Objective: This study aimed to detect occult hepatitis B virus in hepatitis B surface antigen-negative serum using anti-HBc as 
a marker of  previous infection.
Patient and methods: A total of  1000 randomly selected hepatitis B surface antigen-negative sera from blood donors were 
tested for hepatitis B core antibody and hepatitis B surface antibody using an ELISA and nested polymerase chain reaction was 
done using primers specific to the surface gene (S-gene).
Results: Of  the 1000 samples 55 (5.5%)  were found to be reactive, of  which 87.3% (48/55) were positive for hepatitis B sur-
face antibody, indicating immunity as a result of  previous infection however, that does not exclude active infection with escaped 
mutant HBV. Nested PCR results showed the presence of  hepatitis B viral DNA in all the 55 samples that were positive for core 
protein, which is in agreement with the hepatitis B surface antibody result.
Conclusion:  This study reveals the 5.5% prevalence of  occult hepatitis B among Malaysian blood donors as well as the reliabil-
ity of  using hepatitis B core antibody in screening for occult hepatitis B infection in low endemic, low socioeconomic settings.
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Introduction
Hepatitis B surface antigen (HBsAg) is the main diag-
nostic marker for hepatitis B infection and for screen-
ing of  donated blood.  Escaped mutants might be as a 
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result of  post transcriptional effect of  the mutation on 
HBsAg expression as described previously1,2. In addition, 
it is a known fact that surface antigen mutation reduced 
effectiveness of  diagnostics and allowed for humoral im-
mune escaped thereby reducing vaccination effectiveness 
3. While occult hepatitis B is characterised by undetect-
able levels of  surface antigen, but detectable levels of  
viral DNA4. Occult hepatitis B infection is becoming a 
major global threat due to: (a) the effect on the health 
of  children born to carrier mothers despite the presence 
of  passive immunoglobulin at birth5-7; (b) immune escape 
of  current vaccines8,9; and (c) spread through blood and 
blood products in post transfusion infection, organ dona-
tion, and sexual transmission10,11. There are several con-
cerns surrounding occult hepatitis B infection in clinical 
settings, including reduced sensitivity to available diag-
nostic tests, lack of  immunity following vaccination with 
non-mutant HBV variants (vaccine escaped mutant), and 
failure of  passive immunization with HBV immunoglob-
ulin G12. The failure of  diagnostic assays to detect HBV 
poses a major risk to recipients of  blood transfusions or 
organ donations13,14. Since hepatitis B surface mutants are 
stable and can be spread through either vertical or hori-
zontal transmission15, both a highly sensitive molecular 
method and an affordable and reliable serological test are 
required for the diagnosis of  occult hepatitis B infection. 
Therefore, this study aimed at detecting occult hepatitis B 
among hepatitis B surface antigen negative blood donors 
using anti-HBc as a marker and compared these results to 




One thousand serum samples were randomly selected 
from a pool of  hepatitis B surface antigen-negative sera 
from anonymized leftovers from initial blood testing 
of  blood donors at the National Blood Centre in Kuala 
Lumpur, Malaysia. Systematic random sampling random 
selection of  first sample systematic selection through a 




Hepatitis B core antibodies were tested for by using a 
commercially available ELISA kit (DRG International 
Inc. New Jersey, USA). Serum samples were diluted in 
wash solution (1:5). Then, 50 µl of  the diluted serum was 
added to the micro wells, which are coated with puri-
fied recombinant hepatitis B core antigen according to 
the manufacturer’s instructions. The TECAN Magellan 
ELISA reader version 6.4 was used to measure the absor-
bance at 450 nm and the results were interpreted based 
on the optical density (OD).
DNA extraction
HBV  DNA  was  extracted  from  200 µl of  serum  using 
a QIAampBlood mini kit  (Qiagen,  Hilden,  Germany) 
according  to  the manufacturer’s  instruction. Briefly, 20 
μl of  protease was added to the serum in a 1.5 ml tube. 
Then, 200 μl of  cell lysis solution (AL buffer) was added, 
vortexed, and incubated for 10 min at 56°C. The DNA 
was eluted using 50 μl of  elution buffer and stored at 
-20°C until further analysis.
 
Nested Polymerase Chain Reaction (PCR)
Two sets of  published primers were used to amplify the 
hepatitis B S-gene from the DNA extracted from the 
serum samples16 with the first round of  PCR using the 
outer primers, which amplify a 916 bp segment which 
includes the S-gene, under the following conditions: 30 
cycles of  94oC for 5 min, 94oC for 30 sec, 63.8oC for 30 
sec, and 72oC for 60 sec, followed by a final extension 
at 72oC for 10 min. The second round of  PCR was per-
formed using the inner primers, which amplify the 656 
bp S-gene amplicon of  the surface antigen under the fol-
lowing conditions: 30 cycles of  94oC for 5 min, 94oC for 
30 sec, 63.8oC for 30 sec, and 72oC for 60 sec, with a final 
extension at 72oC for 8 min. A 50 µl reaction mixture 
containing 1 µl of  DNA sample, 25 µl PCR pre mixed 
solution (Promega, USA), 1.25 µl of  forward and reverse 
primers(final concentration 0.5 µM), and 21.5 µl of  nucle-
ase free water. This reaction was used for both the first 
and second rounds of  PCR amplification using a thermal 
cycler (Bio-Rad) as described previously16. Genomic hep-
atitis B DNA and no DNA template control were used 
as positive and negative controls, respectively.The PCR 
products were analysed by gel electrophoresis using 1.5% 
(w/v) agarose gel (Seakem LE, USA). PCR products were 
visualised with UV illuminator and the product size was 
determined by comparison to the DNA molecular mark-
er (GeneDireX). Sample bands corresponded to the size 
of  the positive control bands. To ensure that the prim-
ers used in this study specifically amplified the S-gene of  
HBV, they were tested against a DNA sample from an 
HBV-positive serum  that is positive for anti-Hbc, anti-
HBe,  and negative anti-HBs.. The absolute detection lim-
it of  the nested PCR was determined by a 10-fold dilution 
of  the standard HBV-positive serum and the detection 
limit was found to 5 copies per μL.
Data analysis
The data from the findings was analyzed using SPSS sta-
tistic version 20 (Chicago, Illinois). The percentage of  oc-
cult hepatitis B infection prevalence was then calculated.
Ethical approval
Ethical approval to carry out this study was obtained 
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from the Institute for Medical Research (IMR) in Malay-
sia with reference No. NMRR-12-469-11762 and the Fac-
ulty of  Medicine and Health Sciences Ethical Committee, 
Universiti Putra, Malaysia (Ref: UPM/.FPSK/100-9/2-
MJKEtikaPen)..
Results
Of  the 1000 samples that were screened, 5.5% (55/1000) 
were found to be anti-HBc-positive, all of  which were also 
positive for HBV DNA. Additionally, 84.8% (848/1000) 
of  the samples were anti-HBs-positive (Table 1). 
Table 1 Serological markers and molecular detection of HBV DNA. 
 








Positive                  0 848 55 0 55 
Negative 1000 152 945 1000 945 
Total 1000 1000 1000 1000 1000 
 
 
The results of  the nested PCR show the presence of  a 
656 bp fragment, indicating a positive result with the no 
template and blank showing no band as such excluding 
chances of  contaminant from the PCR reagents. Positive 
control also showed a specific band that is similar in size 
with the positive samples confirming its positivity (Figure 
1).
Of  the 5.5% (55/1000) of  the samples that were positive 
for occult hepatitis B, 87.3% (48/55) were also hepatitis B 
surface antibody-positive, indicating immunity as a result 
of  previous infection17, while 12.7% (7/55) were negative 
for the presence of  the antibody. However, none of  these 
samples were hepatitis B surface antigen-positive.
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Discussion
Hepatitis B is of  global health importance with about 350 
million chronic carriers worldwide, constituting a major 
global threat. According to World Health Organization 
(WHO), Western Pacific region accounts for about 50% 
of  the world’s chronic hepatitis B infection18. Likewise, 
in Malaysia the prevalence of  HBV among children de-
creased to 0.4% from 3.0% prior to introduction universal 
infant hepatitis B vaccination19. However, the prevalence 
in general population ranges from 1.5 to 9.8% but report-
ed to be lower (0.4%) among repeated blood donors20. In 
this study HBV DNA was detected in HBsAg-negative 
serum using nested PCR, which is in line with previous 
studies that demonstrated the same result in peripheral 
blood mononuclear cells, serum, and liver samples21-24. 
Nested PCR approach improves the sensitivity of  the 
PCR assay by avoiding artefacts and non- specific binding 
associated with the conventional PCR method as shown 
in this study  In serum, HBV DNA levels are less than 
104 copies/mL25, which is considerably lower than those 
that are HBsAg-positive22,23. The use of  NAT in detect-
ing HBV has been a debatable issue, since the viral load 
in occult infection is usually very low, thereby reducing 
the effectiveness of  NAT testing as shown in this study 
where NAT and HBsAg negative sera of  blood donors 
were  found to be HBV DNA positive by nested PCR 
(Table 1). Therefore, there is a need for a more sensitive 
HBsAg system that is capable of  detecting a very low 
HBsAg level and S gene mutants in order to reduce the 
risk of  transfusion and organ transplant associated hepa-
titis B infection.
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Our finding revealed 5.5% prevalence of  anti-HBc 
among healthy blood donors, which is higher than what 
was reported in Italy26, Egypt27, Germany, UK28 and 
USA29, but less than what was reported in Korea30 and 
Greece31. This study revealed a 100% prevalence of  oc-
cult hepatitis in hepatitis B core antibody-positive healthy 
individuals. This is similar to the frequency reported in 
China32. Additionally, other studies have reported find-
ing occult hepatitis B virus more frequently in individuals 
with anti-HBc-positive serology than in those with anti-
HBc-negative serology 33,34. On the other hand, a preva-
lence of  33.3% was reported in North East China32, as 
compared to 0.11% in Taiwan35. The risk transmission 
depends on presence of  anti-HBs and viral dose; viral 
load: copies/ml x vol. of  plasma, the higher the viral load, 
and the higher the chance of  transmission. Anti-HBs; in 
donor or passive also influence the rate of  transmission. 
Immune status of  the recipient is also an important de-
terminant of  its transmission36. In a look back data from 
Japan and Hong Kong: transmission of  HBV from do-
nors with OHBI was approximately 3%36. In Malaysia 
NAT has been implemented in the National Blood Cen-
tre since 5th November 2007 and was used to test the 
donated blood from others catchment hospitals such as 
Klang, Kajang, Kuala Kubu Baru, Termerloh, Bentong, 
Raub, Kuala Lipis and Seremban. There was sufficient 
evidence to support that the effectiveness of  using NAT 
blood screening test to detect HBV infection in donated 
blood. Hence, reducing the risk of  transfusion associated 
HBV infection. However, it is not cost-effective to imple-
ment it in the low endemic setting as such anti-HBc can 
be considered in such setting.
The risk of  transmitting occult hepatitis B infection de-
pendents on presence of  copies of  HBV DNA in the 
plasma and the volume of  the plasma transfused there-
fore, the higher the viral load in the transfused blood the 
higher the chance of  infectivity37. The presence of  high 
anti-HBs in the donors blood also influence the rate of  
infectivity38. Immune status of  the recipient and donors 
also play an important role in determining infectivity36. 
Recent infectivity data indicate transmission rate 3.8%  38, 
but the rate is higher in unvaccinated recipients of  oc-
cult hepatitis B  blood or blood products. Blood products 
from donors with occult hepatitis B carry a high risk of  
HBV transmission by transfusion. This may justify safety 
measures such as anti-HBc and HBV nucleic acid test 
screening depending on epidemiology. Anti-HBc may be 
used in < 2% to 4% prevalence, while, HBV-NAT in high 
endemic areas37. Occult hepatitis B infections have sig-
nificant clinical importance since they can become reacti-
vated when the immune system is suppressed and can be 
transmitted through blood or blood product transfusion, 
organ transplant, and sexual intercourse. It may also en-
hance the progression of  liver fibrosis and, subsequently, 
hepatocellular carcinoma.
Conclusion
This study revealed a 5.5 % prevalence of  occult hepatitis 
in asymptomatic, healthy blood donors. We found that 
100% of  samples that were positive for hepatitis B core 
antibodies were also positive for HBV DNA, thus indicat-
ing the reliability of  hepatitis B core antibody in screening 
for occult hepatitis B infection, especially in low socio-
economic, low endemic settings. Therefore, compliment-
ing screening methods like anti-HBc and NAT based on 
epidemiology may be of  important benefit in decreasing 
the risk associated with post transfusion HBV infection 
as such anti-HBc may be used in < 2% to 4% prevalence, 
while, HBV-NAT in high endemic areas. The detection 
of  hepatitis B viral DNA in both the so-called “immune 
as a result of  natural infection” and the isolated anti-core 
group indicates the need for further study and reclassifi-
cation.
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